Navigation Links
Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
Date:7/16/2012

SAN DIEGO, July 16, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has filed a Notice of Appeal to the U.S. Court of Appeals for the Federal Circuit from the July 5, 2012 Preliminary Injunction Order of the U.S. District Court for the Northern District of California denying Sequenom's request for preliminary injunctive relief.  Sequenom had previously requested that the district court enjoin Aria Diagnostics' (now Ariosa Diagnostics, Inc.) continued infringement of U.S. Patent No. 6,258,540 ("'540 patent").

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of its products, reliance upon the collaborative efforts of other parties, the Company's financial position, its ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly newer technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K for the year ended December 31, 2011, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
2. Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration
3. Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case
4. Coalition to Save Pure Files Proxy Documents With SEC, Urges Pures Board to Set an Annual Meeting Date
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
7. Notice of Redemption and Withdrawal of Class of Securities from Listing on the NYSE
8. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
9. State-of-the-Art Novelda NVA6000 Impulse Radar Transceiver Finds Widespread Appeal and Applications
10. Sequenom Addresses Preliminary Injunction Decision, Reaffirms Defense of Patent
11. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its ... announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of ... been selected for membership in ARCS Alumni Hall of Fame . ASTER ...
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Biology News(10 mins):